We Build a New
Class of Biotech
Related Sciences (RS) is a data-driven drug discovery studio. RS uses a proprietary machine learning platform to identify the best new drug discovery opportunities for every disease, organizes them into structured investment portfolios, and then operates them leanly over a specialized platform designed to take full advantage of the last decade's transformational R&D and productivity innovations.
Extraordinary Science Deserves a Fresh Model
Scientific entrepreneurs build biotech companies to create better medicines. But what if building a better biotech company could enable those entrepreneurs to succeed more often? We view innovating on biotech's operating, R&D, and business model itself as a critical force-multiplier and accelerator in the quest to bring the next great generation of medicines to patients as quickly as possible. As such, we focus on big questions, like:
What Factors Increase the Chances of Success?
RS spent years quantitatively analyzing all of global biopharma's historical successes and failures in order to elucidate the specific factors that most impact a drug's odds of clinical success, and a company's chances of economic success. What if a new systematic set of principles and strategies based on this could significantly improve success rates? 1, 2, 5
What Models Might Enhance Risk-Reward?
Today ~99.7% of the world’s institutional investors have zero exposure to biotech, with only ~250 firms making 2+ therapeutics investments per year 3. What if new operating and financial models could improve the sector's accessibility and economic appeal, dramatically expanding capital availability for the drugs and companies that truly "deserve to be made"?
Are the Best Discoveries Being Made into Medicines?
Analysis of all current biomedical knowledge on the RS data platform reveals the surprising finding that ~75% of all target-disease opportunities with strong cumulative evidence of links have never been tried: 23,000+ opportunities spanning 3,800+ individual targets for 4,200+ diseases are just waiting to be made into promising new medicines. 4